Abstract
Objective: a morphological study of the transcription factors NeuroD1, Nkx2.2, Isl1; somatostatin and chromogranin A in various forms of CH The methods included immunohistochemistry examination with antibodies to NeuroD1, insulin, somatostatin, ChrA, Nkx2.2, Isl1, and morphometric analysis of pancreas fragments from 18 CH children and 9 pancreases of children, who died of heart failure. Results. Somatostatin was expressed in 26,3±3,3% of endocrine cells (EC) in diffuse CH (DCH), and in 41,1±6,8% of EC in focal CH (FCH). Isl1 was expressed in 59,8±7,1% of EC in DCH and in 87,3±3,2% of EC in FCH. Nkx2.2 was expressed by 55,9±7,9% and 69,3±10,4% of EC in DCH and in FCH respectively. Its expression level was comparable to Isl1 in adenomatous structures and in true adenomas. NeuroD1 was expressed in 58,4±9,7% and 83±4,7% of EC in DCH and in FCH respectively. This transcription factor was expressed by 65,5±7,4% and 77,3±9,4% of exocrine cells in DCH and in FCH respectively. The number of cells with the expression of chromogranin A, Isl1, Nkx2.2 and NeuroD1 in the endocrine part, and NeuroD1 – and in the exocrine part with DCH and FCH was significantly higher than in the normal pancreas. Conclusion. Immunohistochemical analysis established the number of cells expressing chromogranin A, Isl1, Nkx2.2 and NeuroD1 in the endocrine portion to be significantly higher than in the normal pancreas in any form of CH. The most demonstrative marker of CH is NeuroD1.
Keywords
Authors and affiliations
L.B. Mitrofanova, A.O. Hazratov, B.E. Galkovsky, A.A. Sukhotskaya, V.G. Bairov, D.V. Ryzhkova, M.D. Poyda, I.L. Nikitina Almazov National Medical Research Centre, Akkuratova str. 2, St. Petersburg, 197143, Russian Federation E-mail: lubamitr@yandex.ru
References
Stanley C.A. Advances in diagnosis and treatment of hyperinsulinism in infants and children. J. Clin. Endocrinol. Metab. 2002; 87: 4857–9 https://doi.org/10.1210/jc.2002-021403
De León D.D., Stanley C.A. Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin. Pract. Endocrinol. Metab. 2007; 3: 57–68 https://doi.org/10.1038/ncpendmet0368
Demirbilek H. and Hussain K. Congenital Hyperinsulinism: Diagnosis and Treatment Update. J. Clin. Res Pediatr Endocrinol. 2017; 9 (2): 69–87 doi:10.4274/jcrpe.2017.S007
Arnoux J.B., Verkarre V., Saint-Martin C., Montravers F., Brassier A., Valayannopoulos V. et al. Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet J. Rare Dis. 2011; 6: 63 https://doi.org/10.1186/1750-1172-6-63
Senniappan S., Shanti B., James C., Hussain K. Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management. J. Inherit Metab. Dis. 2012; 35: 589–601 https://doi.org/10.1007/s10545-011-9441-2
Sempoux Ch., Guiot Y., Jaubert F., Rahier J. Focal and diffuse forms of congenital hyperinsulinism: The keys for differential diagnosis Endocrine Pathology. 2004; 15 (3): 241–6.
Han B., Mohamed Z., Estebanez M.S. et al. Atypical Forms of Congenital Hyperinsulinism in Infancy Are Associated With Mosaic Patterns of Immature Islet Cells. J. Clin. Endocrinol Metab. 2017; 102 (9): 3261–7 https://doi.org/10.1210/jc.2017-00158
Sweet C.B., Grayson S., Polak M. Management strategies for neonatal hypoglycemia. J. Pediatr Pharmacol Ther. 2013; 18: 199–208 https://doi.org/10.5863/1551-6776-18.3.199
Lord K., De León D.D. Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management. Int J. Pediatr Endocrinol. 2013; 1: 3–12 https://doi.org/10.1186/1687-9856-2013-3
Laje P., States L.J., Zhuang H., Becker S.A., Palladino A.A., Stanley C.A. et al. Accuracy of PET/CT scan in the diagnosis of the focal form of congenital hyperinsulinism. J. Pediatr Surg. 2013; 48: 388–93 https://doi.org/10.1016/j.jpedsurg.2012.11.025
Meintjes M., Endozo R., Dickson J., Erlandsson K., Hussain K., Townsend C. et al. 18F-DOPA PET and enhanced CT imaging for congenital hyperinsulinism: initial UK experience from a technologist’s perspective. Nucl Med Commun. 2013; 34: 601–8 https://doi.org/10.1097/MNM.0b013e32836069d0
Otonkoski T., Näntö-Salonen K., Seppänen M., Veijola R., Huopio H., Hussain K. et al. Noninvasive diagnosis of focal Hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes. 2006; 55: 13–8 https://doi.org/10.2337/diabetes.55.01.06.db05-1128
Oyama K., Sanno N., Teramoto A., Osamura R.Y. Expression of neuro D1 in human normal pituitaries and pituitary adenomas. Modern Pathology. 2001; 14 (9): 892–9 https://doi.org/10.1038/modpathol.3880408
Pataskar A., Jung J., Smialowski P., Noack F. et al. NeuroD1 reprograms chromatin and transcription factor landscapes to induce the neuronal program. The EMBO J. 2016; 35 (1): 24–45 https://doi.org/10.15252/embj.201591206
Liu M., Pereira F.A., Price S.D., Chu M.J., Shope C. et al. Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. Genes & development. 2000; 14 (22): 2839–54 https://doi.org/10.1101/gad.840500
Bell G.I., Polonsky K.S. Diabetes mellitus and genetically programmed defects in β-cell function. Nature. 2001; 414 (6865): 788–91 https://doi.org/10.1038/414788a
Cerf M.E. Transcription factors regulating β-cell function. European Journal of Endocrinology. 2006; 155 (5): 671–9 https://doi.org/10.1530/eje.1.02277
Gu C., Stein G.H., Pan N., Goebbels S., Hörnberg H. et al. Pancreatic β cells require NeuroD to achieve and maintain functional maturity. Cell Metab. 2010; 11 (4): 298–310 https://doi.org/10.1016/j.cmet.2010.03.006
Chae J.H., Stein G.H., Lee J.E. NeuroD: the predicted and the surprising. Mol. Cells. 2004;18: 271–88.
Chao C.S., Loomis Z.L., Lee J.E., Sussel L. Genetic identification of a novel NeuroD1 function in the early differentiation of islet alpha, PP and epsilon cells. Dev Biol. 2007; 312: 523–32 https://doi.org/10.1016/j.ydbio.2007.09.057
Ansari P.I., Marcora E., Geron I., Tyrberg B., Demeterco C. et al. NeuroD1 in the endocrine pancreas: Localization and dual function as an activator and repressor. Developmental Dynamics. 233: 946–53 https://doi.org/10.1002/dvdy.20443
Mastracci T.L., Wilcox C., Panea C., Golden J.A., May C.L. and Sussel L. Nkx2.2 and Arx genetically interact to regulate pancreatic endocrine cell development and endocrine hormone expression. Dev Biol. 2011; 359 (1): 1–11. https://doi.org/10.1016/j.ydbio.2011.08.001
Doyle M.J. and Sussel L. Nkx2.2 Regulates β-Cell Function in the Mature Islet. Diabetes. 2007; 56 (8): 1999–2007.
Anderson K.R., Torres C.A., Solomon K., Becker T.C., Newgard C.B. et al. Cooperative Transcriptional Regulation of the Essential Pancreatic Islet Gene NeuroD1 (Beta2) by Nkx2.2 and Neurogenin 3. J. Biol. Chem. 2009; 284 (45): 31236–48. https://doi.org/10.1074/jbc.M109.048694
Guo T., Wang W., Zhang H., Liu Y., Chen P. et al. Promotes Pancreatic Islet Cell Proliferation. PLoS One. 2011; 6 (8): e22387. https://doi.org/10.1371/journal.pone.0022387
Krivova Ju.S., Barabanov V.M., Proschina A.E., Savel'ev S.V. Raspredelenie hromogranina A v podzheludochnoj zheleze plodov cheloveka. Bjulleten' eksperimental'noj biologii i meditsiny. 2013; 156 (12): 839–42. [Krivova Yu.S., Barabanov V.M., Proschina A.E., Saveliev S.V. Distribution of chromogranin A in the pancreas of human fetuses. Byulleten Eksperimentalnoj Biologii i Mediciny. 2013; 156 (12): 839–42 (in Russian)]
Strowski M.Z., Parmar R.M., Blake A.D., Schaeffer J.M. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology. 2000; 141 (1): 111–7 https://doi.org/10.1210/endo.141.1.7263
Bremer A.A., Nobuhara K.K., Gitelman S.E. Congenital hyperinsulinism in an infant caused by a macroscopic insulin-producing lesion. J. Pediatr Endocrinol Metab. 2007; 20 (3): 437–40.
Suchi M. The Pancreas in Stocker & Dehner’s Pediatric pathology [edited by] Stocker J.T., Dehner L.P. Husain A.N. – 3rd ed. 2011Wolters Kluwer. Lippincott Williams&Wilkins: Philadelphia – Tokyo, 743–79.
Sempoux C., Capito C., Bellanné-Chantelot C., Verkarre V., de Lonlay P., Aigrain Y. et al. Morphological mosaicism of the pancreatic islets: a novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy. J. Clin. Endocrinol. Metab. 2011; 96: 3785–93 (MEDIUM). https://doi.org/10.1210/jc.2010-3032
Goel P., Choudhury S.R. Persistent hyperinsulinemic hypoglycemia of infancy: An overview of current concepts. J. Indian Assoc Pediatr Surg. 2012; 17 (3): 99–103 https://doi.org/10.4103/0971-9261.98119
Gu C., Stein G.H., Pan N. et al. Pancreatic beta cells require NeuroD to achieve and maintain functional maturity. Cell Metab. 2010; 11 (4): 298–310. https://doi.org/10.1016/j.cmet.2010.03.006
Lejonklou M.H., Edfeldt K., Johansson T.A., Stålberg P., Skogseid B. Neurogenin 3 and neurogenic differentiation 1 are retained in the cytoplasm of multiple endocrine neoplasia type 1 islet and pancreatic endocrine tumor cells. Pancreas. 2009; 38 (3): 259–66. https://doi.org/10.1097/MPA.0b013e3181930818.
De Lonlay P., Simon-Carre A., Ribeiro M.J., Boddaert N., Giurgea I., Laborde K., Bellanné-Chantelot C., Verkarre V., Polak M., Rahier J., Syrota A., Seidenwurm D., Nihoul-Fékété C., Robert J.J., Brunelle F., Jaubert F. Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion. J. Clin. Endocrinol. Metab. 2006; 91 (3): 933–40. Epub 2006 Jan 10.
Ahren B. Autonomic regulation of islet hormone secretion—implications for health and disease. Diabetologia. 2000; 43: 393–410 https://doi.org/10.1007/s001250051322
Jetton T.L., Liang Y., Cincotta A.H. Systemic treatment with sympatholytic dopamine agonists improves aberrant -cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob/ob mice. Metabolism. 2001; 50: 1377–84.
Konturek S.J., Zabielski R., Konturek J.W., Czarnecki J. Neuroendocrinology of the pancreas; role of brain-gut axis in pancreatic secretion. Eur. J. Pharmacol. 2003; 481: 1–14 https://doi.org/10.1016/j.ejphar.2003.08.042
Al-Brahim N.Y.Y., Asa S.L. My approach to pathology of the pituitary gland J. Clin. Pathol. 2006; 59: 1245–253 https://doi.org/10.1136/jcp.2005.031187
Rodriguez M.J., Saura J., Finch C.C., Mahy N., Billett E.E. Localization of monoamine oxidase A and B in human pancreas, thyroid, and adrenal glands. J. Histochem Cytochem. 2000; 48: 147–51 https://doi.org/10.1177/002215540004800115
Orlefors H., Sundin A., Fasth K.J., Oberg K., Langstrom B., Eriksson B., Bergstrom M. Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmine. Nucl. Med. Biol. 2003; 30: 669–79 https://doi.org/10.1016/S0969-8051(03)00034-9
Mezey E., Eisenhofer G., Harta G., Hansson S., Gould L., Hunyady B., Hoffman B.J. A novel nonneuronal catecholaminergic system: exocrine pancreas synthesizes and releases dopamine. Proc Natl Acad Sci USA. 1996; 93: 10377–82.
Ericson L.E., Hakanson R., Lundquist I. Accumulation of dopamine in mouse pancreatic B-cells following injection of l-DOPA. Localization to secretory granules and inhibition of insulin secretion. Diabetologia. 1977; 13: 117–24 https://doi.org/10.1007/BF00745138
Du A., Hunter C.S., Murray J. et al. Islet-1 is required for the maturation, proliferation, and survival of the endocrine pancreas. Diabetes. 2009; 58 (9): 2059–69 https://doi.org/10.2337/db08-0987
Mastracci T.L., Wilcox C.L., Arnes L. et al. Nkx2.2 and Arx genetically interact to regulate pancreatic endocrine cell development and endocrine hormone expression. Dev Biol. 2011; 359 (1): 1–11 https://doi.org/10.1016/j.ydbio.2011.08.001
Papizan J.B., Singer R.A., Tschen S.-I., Dhawan S., Friel J.M., Hipkens S.B. et al. Nkx2.2 repressor complex regulates islet β-cell specification and prevents β-to-α-cell reprogramming. Genes Dev. 2011; 25 (21): 2291–305 https://doi.org/10.1101/gad.173039.111
Han B., Mohamed Z., Estebanez M.S., Craigie R.J., Newbould M., Cheesman E. et al. Atypical Forms of Congenital Hyperinsulinism in Infancy Are Associated With Mosaic Patterns of Immature Islet Cells. The Journal of Clinical Endocrinology & Metabolism. 2017; 102 (9): 3261–7 https://doi.org/10.1210/jc.2017-00158